Blogs
Explore our latest pharmaceutical and healthcare blogs for expert perspectives, strategic insights, and emerging trends across R&D, market access, digital health, and regulatory science—curated to inform, inspire, and empower your next move.
A drug's clinical trial data tells you how it performs…
Clinical Differentiation Is No Longer Enough: How "Access Differentiation" Is Becoming the Real Moat
A therapy can post best-in-class trial data and still stall…
For nearly two decades, rare diseases have lived in a…
Why the most successful commercial launches are built long before…
Real-world evidence is no longer optional in market access discussions.…
For many biopharma teams, Phase III is treated as the…
The Inflation Reduction Act (IRA) continues to reshape the U.S.…
The Collapse & Comeback of Digital Therapeutics: What the Industry Learned and Where It’s Going Next
For a few years, digital therapeutics were treated as inevitable.…
Cell and gene therapies are no longer a niche category.…
The quiet truth about rare disease medicines is that a…
Japan has quietly turned its HTA framework into one of…
For years, the United States and the United Kingdom have…
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.